Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: bob zagorin who wrote (28392)	2/25/1999 3:28:00 AM
From: Cheryl Galt	Read Replies (1) \| Respond to of 32384

The San Diego Union-Tribune ran a story that included a comment from analyst Richard van den Broek of Hambrecht & Quist. The article also implies that the trial for Targretin for CTCL is still ongoing. I thought it was complete. Does anyone know? uniontrib.com (This link is permanent) Regards, Cheryl

To: bob zagorin who wrote (28392)	2/25/1999 7:13:00 AM
From: Mudcat	Respond to of 32384

<BOP continues very high today at 93/100...solid green> Just more proof that BOP is a worthless indicator for LGND!

To: bob zagorin who wrote (28392)	2/27/1999 10:12:00 AM
From: tonyt	Respond to of 32384

What's your take on Murphy's recent admission that one of his mistakes was 'emphasizing biotechnology stocks'? Has he made this admission to his subscribers? "So what has hurt Monterey Murphy Technology? "I made two strategic mistakes," the 57-year-old Mr. Murphy says. His technology fund emphasized biotechnology stocks rather than the better-performing electronic-technology stocks that typically dominate tech funds. And Mr. Murphy ignored most of the largest technology companies, recently stellar stock-market performers, to load up on tiny companies that continue to languish at cheap prices."